pravastatin has been researched along with pitavastatin in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.17) | 18.2507 |
| 2000's | 16 (22.22) | 29.6817 |
| 2010's | 47 (65.28) | 24.3611 |
| 2020's | 6 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aoki, T; Kimata, H; Kitahara, M; Kojima, J; Nakagawa, S; Nishimura, H; Saito, Y; Sakashita, M; Sato, F; Suzuki, H; Tamaki, T; Toyoda, K; Wada, Y; Yokoo, N | 1 |
| Kanaki, T; Kitahara, M; Miyakoshi, C; Saito, Y; Tamaki, T; Tanaka, S; Toyoda, K | 1 |
| Fukuda, N; Goto, H; Jayasooriya, AP; Ogawa, Y; Sakono, M; Todaka, N; Yamamoto, K | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Goto, Y; Hata, Y; Itakura, H; Mabuchi, H; Nakaya, N; Ogawa, N; Saito, Y; Sasaki, J; Teramoto, T; Tushima, M; Yamada, N | 1 |
| Abe, T; Endou, H; Kikuchi, R; Kusuhara, H; Sugiyama, Y | 1 |
| Asano, Y; Asanuma, H; Fujita, M; Hirata, A; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Minamino, T; Mori, H; Node, K; Ogai, A; Okuda, H; Sanada, S; Shinozaki, Y; Takashima, S; Tomoike, H | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Miyashita, Y; Murano, T; Oyama, T; Saiki, A; Shirai, K; Watanabe, F | 1 |
| Fujino, M; Kawamura, A; Matsuo, Y; Miura, S; Saku, K; Tanigawa, H | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Hayashi, T; Ka, Y; Kitamura, A; Matsumura, Y; Mori, T; Ohkita, M; Sugii, M; Takaoka, M | 1 |
| Deng, JW; Kim, KB; Liu, KH; Shin, JG; Shon, JH; Song, IS; Zhou, HH | 1 |
| Abe, M; Fukuhara, A; Kobayashi, H; Komuro, R; Matsuda, M; Miyata, Y; Nakayama, Y; Shimomura, I | 1 |
| Cho, DY; Deng, JW; Shin, HJ; Shin, JG; Shon, JH; Song, IS; Yeo, CW | 1 |
| Fujii, T; Kuwano, H; Onimaru, M; Sueishi, K; Yonemitsu, Y | 1 |
| Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T | 1 |
| Fukumoto, Y; Rashid, M; Seto, M; Shimokawa, H; Tawara, S; Yano, K | 1 |
| Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozue, T; Sato, A; Sozu, T; Takeyama, Y; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Endo, C; Kitamura, S; Kusuhara, H; Miyajima, M; Ose, A; Sugiyama, Y; Tohyama, K | 1 |
| Watson, KE | 1 |
| Akishita, M; Eto, M; Iijima, K; Kahyo, T; Kano, MR; Ogawa, S; Ota, H; Ouchi, Y; Setou, M | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Betteridge, J | 1 |
| Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T | 1 |
| Arai, H; Minami, M; Murayama, T; Tamura, Y; Yokode, M | 1 |
| Lin, ZQ; Yang, J; Yin, XF | 1 |
| Inoguchi, T; Kimura, S; Maeda, Y; Sonoda, N; Takayanagi, R; Yokomizo, H | 1 |
| Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozue, T; Sato, A; Sozu, T; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Galetin, A; Houston, JB; Kenworthy, KE; Ménochet, K | 1 |
| Budinski, D; Gosho, M; Hounslow, N; Stender, S | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Nozue, T; Onishi, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozato, T; Nozue, T; Onishi, Y; Sato, A; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 4 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozato, T; Nozue, T; Onishi, Y; Sato, A; Takeyama, Y; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Hattori, H; Hirano, T; Ishihara, M; Iwasaki, T; Kawashiri, MA; Michishita, I; Nozue, T; Yamagishi, M | 1 |
| Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Morino, Y; Nozue, T; Onishi, Y; Sozu, T; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Chapman, MJ; Giral, P; Hounslow, N; Orsoni, A; Robillard, P; Sponseller, CA | 1 |
| Campbell, SE; Davidson, MH; Kryzhanovski, VA; Morgan, RE; Sponseller, CA | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Baek, SH; Cho, HJ; Jeon, HK; Kang, SM; Kim, HY; Lee, HY; Shin, JH | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Shin, DH; Suh, Y | 1 |
| Arai, M; Kako, N; Kawasaki, M; Minatoguchi, S; Miwa, H; Nagaya, M; Noda, T; Onishi, N; Ono, K; Saeki, M; Sato, N; Tanaka, R; Watanabe, S; Watanabe, T | 1 |
| Zhao, SP; Zhao, W | 1 |
| D'Agostino, RB; Jones, SR; Joshi, PH; Martin, SS; Massaro, JM; Miller, PE; Sponseller, CA; Toth, PP | 1 |
| Asaumi, R; Kotani, N; Kusuhara, H; Maeda, K; Nakada, T; Sugiyama, Y; Toshimoto, K; Yoshida, K; Yoshikado, T | 1 |
| Jiang, M; Liu, TT; Pan, DQ; Shi, JH; Wang, Q | 1 |
| Banach, M; Blaha, MJ; Chruściel, P; Jones, SR; Lip, GY; Martin, SS; Mikhailidis, DP; Mosteoru, S; Pencina, MJ; Ray, KK; Rembek-Wieliczko, M; Rysz, J; Sahebkar, A; Serban, MC; Toth, PP; Ursoniu, S | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| D'Agostino, RB; Jones, SR; Joshi, PH; Kulkarni, KR; Martin, SS; Massaro, JM; Miller, PE; Sponseller, C; Toth, PP | 1 |
| Aberg, JA; Burdo, TH; Fitch, KV; Grinspoon, SK; McCurdy Pate, M; Sanchez, L; Sponseller, CA; Toribio, M; Williams, KC; Zanni, MV | 1 |
| Aberg, JA; Campbell, SE; Kryzhanovski, VA; Sponseller, CA; Thompson, MA; Ward, DJ | 1 |
| Kanamitsu, K; Kusuhara, H; Schuetz, JD; Sugiyama, Y; Takeuchi, K | 1 |
| Ikejiri, K; Kusuhara, H; Maeda, K; Nakada, T; Sugiyama, Y; Toshimoto, K; Yoshikado, T | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Barton, HA; Li, R | 1 |
| Kume, T; Takahashi, T; Uno, Y; Yamazaki, H | 1 |
| Benet, LZ; Bowman, CM; Okochi, H | 1 |
| Betteridge, DJ; Carmena, R | 1 |
| Bowman, CM; Chen, E; Chen, L; Chen, Y; Chen, YC; Liang, X; Mao, J; Wright, M | 1 |
| Avihingsanon, A; Bautista-Arredondo, S; Bendavid, E; Boettiger, DC; Chaiwarith, R; Chattranukulchai, P; Kahn, JG; Khusuwan, S; Kiertiburanakul, S; Law, MG; Newall, AT; Phillips, A; Ross, J | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Fraser, IP; Guo, Z; Iwamoto, M; Levine, V; Panebianco, D; Prueksaritanont, T; Swearingen, D; Wolford, D; Yeh, WW | 1 |
| Bowman, CM; Chen, B; Chen, Y; Cheong, J; Liu, L; Mao, J | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
7 review(s) available for pravastatin and pitavastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Regression Analysis; Rosuvastatin Calcium; Simvastatin | 2016 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Diabetogenic Action of Statins: Mechanisms.
Topics: Aged; Animals; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin; Male; Metabolic Syndrome; Mice; Middle Aged; Pravastatin; Quinolines; Risk Factors | 2019 |
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
27 trial(s) available for pravastatin and pitavastatin
| Article | Year |
|---|---|
A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Quinolines; Safety | 2002 |
The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
Topics: Adult; Anticholesteremic Agents; Biological Transport; Cross-Over Studies; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Inactivation, Metabolic; Indoles; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Oocytes; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Protein Binding; Quinolines; Substrate Specificity | 2008 |
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Leukocytes; Male; Pravastatin; Pyrroles; Quinolines; rac1 GTP-Binding Protein; ras Proteins; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2009 |
Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology (TRUTH Study): rationale and design.
Topics: Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Endpoint Determination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pravastatin; Prospective Studies; Quinolines; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Male; Pravastatin; Quinolines; Treatment Outcome | 2012 |
Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis.
Topics: Aged; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
Topics: Aged; Aged, 80 and over; Cholesterol, LDL; Double-Blind Method; Drug Tolerance; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Quinolines; Time Factors; Treatment Outcome | 2013 |
Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: subanalysis of the TRUTH study.
Topics: Aged; Biomarkers; Coronary Artery Disease; Coronary Vessels; Dyslipidemias; Female; Fibrosis; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney; Kidney Diseases; Lipids; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease.
Topics: Aged; Biomarkers; Chromatography, Gas; Coronary Artery Disease; Coronary Vessels; Disease Progression; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Prospective Studies; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease.
Topics: Aged; alpha-Linolenic Acid; Arachidonic Acid; Cholesterol, LDL; Coronary Artery Disease; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Longitudinal Studies; Male; Middle Aged; Pravastatin; Prospective Studies; Quinolines | 2013 |
Comparison of change in coronary atherosclerosis in patients with stable versus unstable angina pectoris receiving statin therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] s
Topics: Aged; Angina, Stable; Angina, Unstable; Biomarkers; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Plaque, Atherosclerotic; Pravastatin; Quinolines; Regression Analysis; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
Topics: Aged; Apoptosis; Biomarkers; Coronary Artery Disease; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Quinolines; Serine Endopeptidases; Severity of Illness Index; Treatment Outcome | 2013 |
Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention.
Topics: Aged; Atherosclerosis; Biomarkers; Coronary Artery Disease; Dose-Response Relationship, Drug; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
C-reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: the extended TRUTH study.
Topics: Aged; Angina Pectoris; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Japan; Male; Middle Aged; Myocardial Infarction; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Regression Analysis; Risk Factors; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies.
Topics: Blood Glucose; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Quinolines; Triglycerides | 2014 |
Comparison of the effects of pitavastatin versus pravastatin on coronary artery plaque phenotype assessed by tissue characterization using serial virtual histology intravascular ultrasound.
Topics: Acute Coronary Syndrome; Aged; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Necrosis; Phenotype; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Ultrasonography, Interventional | 2015 |
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Topics: Aged; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Prospective Studies; Quinolines; Triglycerides | 2014 |
Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.
Topics: Aged; Biomarkers; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Prospective Studies; Quinolines; Recovery of Function; Republic of Korea; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Impact of statin treatment on strut coverage after drug-eluting stent implantation.
Topics: Adult; Coronary Angiography; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prosthesis Implantation; Quinolines; Tomography, Optical Coherence; Treatment Outcome | 2015 |
Anti-inflammatory and morphologic effects of pitavastatin on carotid arteries and thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: a prospective randomized comparative study with pravastatin (EPICENTRE study).
Topics: Aged; Anti-Inflammatory Agents; Atherosclerosis; Carotid Arteries; Echocardiography, Transesophageal; Female; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Pravastatin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Systems Integration; Thoracic Arteries; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia.
Topics: Aged; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Quinolines | 2016 |
Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Double-Blind Method; Dyslipidemias; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Pravastatin; Quinolines; Treatment Outcome; Ultracentrifugation; Young Adult | 2017 |
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.
Topics: Anticholesteremic Agents; Arteritis; Biomarkers; Double-Blind Method; HIV Infections; Humans; Immunologic Factors; Pravastatin; Quinolines; Treatment Outcome | 2017 |
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; HIV Infections; Humans; Male; Middle Aged; Placebos; Pravastatin; Puerto Rico; Quinolines; Treatment Outcome; United States; Young Adult | 2017 |
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Proteins; Pravastatin; Quinolines; Quinoxalines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2021 |
38 other study(ies) available for pravastatin and pitavastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship | 2016 |
Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Animals; Dogs; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipids; Liver; Lovastatin; Male; Pravastatin; Quinolines; Rats; Rats, Wistar; Simvastatin; Sterols | 1997 |
NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery.
Topics: Animals; Aorta; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Cell Line; DNA; Eukaryotic Cells; Extracellular Matrix; Fibronectins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Quinolines; Rabbits; Simvastatin; Transforming Growth Factor beta; Tunica Intima; Tunica Media | 1998 |
Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver.
Topics: Animals; Binding, Competitive; Fatty Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Microsomes, Liver; Oxidation-Reduction; Pravastatin; Quinolines; Rats; Rats, Wistar; Simvastatin; Triglycerides | 1999 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain; Carrier Proteins; Digoxin; DNA, Complementary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Kinetics; Male; Microinjections; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pravastatin; Quinolines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Taurocholic Acid | 2004 |
Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Androstadienes; Animals; Cardiotonic Agents; Chromones; Coronary Disease; Dogs; Dose-Response Relationship, Drug; Enzyme Activation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morpholines; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pravastatin; Pyridines; Quinolines; Signal Transduction; Theophylline; Wortmannin | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Atorvastatin; Cell Culture Techniques; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Mice; Pioglitazone; PPAR gamma; Pravastatin; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Thiazolidinediones | 2005 |
Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase.
Topics: Anticholesteremic Agents; Cell Division; Chemokine CCL2; Chemokine CCL5; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Humans; Monocytes; Pravastatin; Quinolines; Receptors, CCR2; Receptors, CCR5; Receptors, Chemokine; S Phase; U937 Cells; Up-Regulation | 2006 |
Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.
Topics: Animals; Aorta; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Pyridines; Pyrroles; Quinolines; RNA, Messenger; Swine | 2006 |
Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study.
Topics: Chromatography, Liquid; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Quinolines; Tandem Mass Spectrometry | 2008 |
Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon Regulatory Factor-3; Interferon-beta; Interleukin-6; Macrophages; Male; Mice; Mice, Obese; Myeloid Differentiation Factor 88; Obesity; Pravastatin; Quinolines; Signal Transduction; Toll-Like Receptor 4 | 2008 |
Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression.
Topics: Animals; Becaplermin; Blood Glucose; Cells, Cultured; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Foot; Enzyme Inhibitors; Genetic Therapy; Glycation End Products, Advanced; Hindlimb; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet-Derived Growth Factor; Pravastatin; Proto-Oncogene Proteins c-sis; Quinolines; Regional Blood Flow; Signal Transduction; Time Factors; Up-Regulation | 2008 |
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies | 2008 |
Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Capillaries; Cell Line; Cell Membrane; Cerebral Cortex; Choroid Plexus; Digoxin; Enkephalin, D-Penicillamine (2,5)-; Fluorobenzenes; Gene Expression; Humans; Ion Pumps; Kinetics; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Ochratoxins; Organic Anion Transporters; Organic Cation Transport Proteins; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Quinolines; Recombinant Proteins; Rosuvastatin Calcium; Sulfonamides; Taurocholic Acid; Tetrahydroisoquinolines; Transfection | 2010 |
Pitavastatin: the newest HMG-CoA reductase inhibitor.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin | 2010 |
Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway.
Topics: Animals; Atorvastatin; Catalase; Cellular Senescence; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sirtuin 1; Umbilical Veins | 2010 |
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome | 2011 |
Differential effect of statins on diabetic nephropathy in db/db mice.
Topics: Adiposity; Albuminuria; Animals; Blood Pressure; Body Weight; Creatinine; Diabetic Nephropathies; Fluorobenzenes; Insulin Resistance; Male; Mice; Oxidative Stress; Pravastatin; Pyrimidines; Quinolines; Real-Time Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Prediction of the pharmacokinetic drug-drug interaction of pravastatin and pitavastatin with cyclosporine by a digital liver model based on metabolism and transporter].
Topics: Animals; Area Under Curve; Biological Transport; Computer Simulation; Cyclosporine; Drug Interactions; Humans; Liver; Metabolic Clearance Rate; Models, Biological; Pravastatin; Quinolines | 2011 |
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Transport; Bosentan; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorobenzenes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kinetics; Models, Biological; Organic Anion Transporters; Piperidines; Pravastatin; Pyrimidines; Quinolines; Rats; Rosuvastatin Calcium; Species Specificity; Sulfonamides; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Different effects of statins on induction of diabetes mellitus: an experimental study.
Topics: Atorvastatin; Cell Cycle; Cell Survival; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Muscle, Skeletal; Pravastatin; Quinolines; Rosuvastatin Calcium; Signal Transduction; Structure-Activity Relationship | 2015 |
Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
Topics: Antibiotics, Antitubercular; Computer Simulation; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Models, Biological; Organic Anion Transporters; Pravastatin; Quinolines; Rifampin | 2016 |
Characterization of interactions of simvastatin, pravastatin, fluvastatin, and pitavastatin with bovine serum albumin: multiple spectroscopic and molecular docking.
Topics: Animals; Binding Sites; Cattle; Fatty Acids, Monounsaturated; Fluvastatin; Hydrogen Bonding; Indoles; Kinetics; Molecular Docking Simulation; Pravastatin; Protein Binding; Quinolines; Serum Albumin, Bovine; Simvastatin; Solutions; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Thermodynamics | 2017 |
Investigation of the Importance of Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) in the Active Efflux of Anionic Drugs Across the Blood-Brain Barrier.
Topics: 2,4-Dichlorophenoxyacetic Acid; Acridines; Adenosine Triphosphate; Animals; Biological Transport; Blood-Brain Barrier; Brain; Central Nervous System; Cyclic GMP; Humans; Kinetics; Male; Methotrexate; Mice, Inbred C57BL; Multidrug Resistance-Associated Proteins; Ochratoxins; Pravastatin; Quinazolines; Quinolines; Tetrahydroisoquinolines; Thiophenes; Uric Acid | 2017 |
Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins.
Topics: Animals; Biological Transport; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Membrane Potentials; Organic Anion Transporters; Permeability; Pravastatin; Quinolines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Topics: Asian People; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbamates; Computer Simulation; Gene Frequency; Genotype; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Models, Biological; Neoplasm Proteins; Pharmacogenomic Variants; Phenotype; Piperidines; Pravastatin; Quinolines; Rosuvastatin Calcium; White People | 2018 |
Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes.
Topics: Animals; Drug Interactions; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Macaca fascicularis; Macaca mulatta; Organic Anion Transporters; Plasmids; Pravastatin; Quinolines; Recombinant Proteins; Rosuvastatin Calcium; Solute Carrier Organic Anion Transporter Family Member 1B3; Substrate Specificity; Telmisartan | 2019 |
The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation.
Topics: Animals; Atorvastatin; Biological Transport; Cells, Cultured; Hepatocytes; Kinetics; Liver; Membrane Transport Proteins; Metabolic Clearance Rate; Organic Anion Transporters; Pravastatin; Protein Binding; Quinolines; Rats; Rosuvastatin Calcium | 2019 |
Changes in Organic Anion Transporting Polypeptide Uptake in HEK293 Overexpressing Cells in the Presence and Absence of Human Plasma.
Topics: Blood Proteins; Cell Culture Techniques; Culture Media; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Pravastatin; Protein Binding; Quinolines; Rosuvastatin Calcium; Solute Carrier Organic Anion Transporter Family Member 1B3; Substrate Specificity | 2020 |
Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
Topics: Adult; Atherosclerosis; Cost-Benefit Analysis; Drug Costs; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quality-Adjusted Life Years; Quinolines; Thailand | 2020 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Improving the Translation of Organic Anion Transporting Polypeptide Substrates using HEK293 Cell Data in the Presence and Absence of Human Plasma via Physiologically Based Pharmacokinetic Modeling.
Topics: Administration, Intravenous; Carbamates; Drug Discovery; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Models, Biological; Piperidines; Plasma; Pravastatin; Quinolines; Rosuvastatin Calcium; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2021 |